Since they had "no control" over the patient trial, can we even be sure that the patients suffered from aplastic anemia? It may be that Koos and Lander were cautious because these patients suffered from the effects of chemo depleting blood cell counts, but were not necessarily in the pool of patients RGBP has the go ahead for in aplastic anemia. Just a thought.
But even this doesn't take away from the positive that the tests were positive, the patients tolerated HemaX and there are patients that can benefit from HemaX.
News 
Market Data 
Discover 
AI
